Olga Y. Vinogradova

Moscow, MOW, Russian Federation

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis.

ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis.

Journal: Blood advances
Published: January 09, 2025

Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia.

Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia.

Journal: Annals of hematology
Published: October 27, 2024

The Features of COVID-19's Course and the Efficacy of the Gam-COVID-Vac Vaccine in Patients with Paroxysmal Nocturnal Hemoglobinuria.

The Features of COVID-19's Course and the Efficacy of the Gam-COVID-Vac Vaccine in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Journal: Hematology reports
Published: March 20, 2023

Multiple myeloma: response to treatment and survival of patients according to the interim analysis of the Russian observational, retrospective-prospective, multicenter cohort study (MULTISPECT)

Multiple myeloma: response to treatment and survival of patients according to the interim analysis of the Russian observational, retrospective-prospective, multicenter cohort study (MULTISPECT)

Journal: Terapevticheskii arkhiv
Published: August 09, 2022

Relationship Between Markers of the Acute Phase of Inflammation, Parameters of Blood Lipid Composition and Intracardiac Hemodynamics During Chemotherapy in Patients With Multiple Myeloma.

Relationship Between Markers of the Acute Phase of Inflammation, Parameters of Blood Lipid Composition and Intracardiac Hemodynamics During Chemotherapy in Patients With Multiple Myeloma.

Journal: Kardiologiia
Published: May 27, 2022

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience

Journal: Terapevticheskii arkhiv
Published: July 20, 2021

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.

Journal: Blood cancer journal
Published: June 25, 2021

Epidemiology of multiple myeloma in city Moscow

Epidemiology of multiple myeloma in city Moscow

Journal: Terapevticheskii arkhiv
Published: April 16, 2020

Analysis of the Mortality of Russian Patients With Chronic Myeloid Leukemia in the Multicenter EUTOS ELN Population-based Study (EUTOS-PBS).

Analysis of the Mortality of Russian Patients With Chronic Myeloid Leukemia in the Multicenter EUTOS ELN Population-based Study (EUTOS-PBS).

Journal: Clinical lymphoma, myeloma & leukemia
Published: November 19, 2019

Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.

Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.

Journal: Terapevticheskii arkhiv
Published: February 01, 2019

Successful treatment for Hodgkin's lymphoma in a female patient with Ph+ chronic myeloid leukemia

Successful treatment for Hodgkin's lymphoma in a female patient with Ph+ chronic myeloid leukemia

Journal: Terapevticheskii arkhiv
Published: December 21, 2012
Showing 1-11 of 11

Last Updated: 09/26/2026